Product Introduction: VOGLIBOZ-0.3

VOGLIBOZ-0.3 is a widely prescribed oral antidiabetic tablet manufactured by Knoll. Composed of 0.3mg of Voglibose, this tablet is indicated for the treatment of post-prandial hyperglycemia in patients diagnosed with Type 2 Diabetes Mellitus. When used alongside a balanced diet and regular physical exercise, it helps regulate blood glucose levels.

Primary Indications

• Management of post-prandial hyperglycemia in Type 2 Diabetes Mellitus.
• Preventing post-meal blood glucose spikes and stabilizing fasting blood sugar levels.
• Reducing the long-term risk of diabetic microvascular and macrovascular complications.

Clinical Benefits

• Post-Meal Regulation: Specifically targets and reduces post-prandial blood glucose spikes.
• Weight Neutrality: Does not cause weight gain and is well-tolerated.
• Glucose-Dependent Action: Low risk of hypoglycemia when used as monotherapy.

Possible Side Effects

Common side effects may include:

• Gastrointestinal issues (abdominal bloating, flatulence, transient diarrhea due to carbohydrate fermentation in colon).
• Mild nausea or dizziness.
• Hypoglycemia (low blood sugar), especially when co-administered with sulfonylureas or insulin.

How to Take VOGLIBOZ-0.3

• Take the tablet immediately before or with your main meal to ensure it acts on dietary carbohydrates.
• Swallow the tablet whole with a glass of water. Do not crush, chew, or split.
• Do not stop taking the drug abruptly without consulting your endocrinologist.

Mechanism of Action

VOGLIBOZ-0.3 contains Voglibose, an alpha-glucosidase inhibitor. It competitively inhibits the intestinal alpha-glucosidase enzymes (sucrase, maltase) responsible for the hydrolysis of disaccharides and oligosaccharides into glucose. This delays carbohydrate digestion and glucose absorption, preventing post-prandial spikes.

Safety Warnings

• Intestinal Obstruction: Contraindicated in patients with severe gastrointestinal disease, hernia, or bowel obstruction.
• Pregnancy & Nursing: Strictly contraindicated. Avoid use.
• Liver Health: Use with caution in patients with hepatic impairment.

Patient Advice

• Always carry a rapid-acting source of sugar (like glucose powder or fruit juice) in case of hypoglycemia.
• Report any persistent, severe flatulence or abdominal cramps to your doctor.
• Ensure regular monitoring of HbA1c levels.

Fact Box

Drug Interactions

• Insulin & Sulfonylureas: Concomitant use increases the risk of hypoglycemia; lower doses may be required.
• Adsorbents (Charcoal): May reduce the absorption and efficacy of voglibose.

User Feedback

• Patients report excellent control of their post-meal sugar levels, with a significant drop in HbA1c.
• Initial stomach flatulence is common but typically decreases after a few weeks of consistent use.